September is  

#WorldAlzheimersMonth

COVID-19 Pandemic Update:

At Vivoryon, our primary concern remains adhering to government regulations to ensure our employees and their families are safe as we continue moving operations forward to the best of our abilities.
As the situation continues to evolve, we will provide updates should the pandemic have any direct effects on our business operations or clinical trials.

Our Story

Vivoryon Therapeutics has an experienced discovery and development team with a strong track record in delivering therapies to patients. We have product candidates in both clinical and preclinical development and are focusing on age-related diseases with unmet medical need.

We are relentless and focused on putting patients at the center of everything we do and strive to develop life-changing medicines.

Our Strategy

Identify and rapidly develop product candidates with clear biology, validated mechanisms and the potential to deliver life-changing improvement to patients suffering from age-related diseases.

1

first-in-class clinical phase 2 molecule in Alzheimer’s disease

1

clinical phase 1/2 ready first-in-class molecule for cancer immune checkpoint inhibition

40

patent families around QPCT and QPCTL inhibitors

12+ years

track-record of bringing drugs from research into clinic

60+

in vivo characterized small molecule inhibitors for cancer immune checkpoint inhibition

1

family of diabetes blockbuster drugs based on our research